title: [Clinical efficacy of tosufloxacin in children with pneumonia due to Mycoplasma pneumoniae].
abstract: We retrospectively examined pediatric 83 patients with pneumonia due to Mycoplasma pneumoniae, ranging in age from 6 months to 14 years, treated with tosufloxacin (TFLX) for more than 3 days between October 2010 and December 2011. The TFLX dose was 12 mg/kg/day (maximum 360 mg/day). Seventy-eight of the 83 children treated with this drug showed symptom amelioration, and the response rate to the drug was 94.0%. The remaining 5 patients showed no improvement despite drug administration for 3 to 6 days, and TFLX was switched to minocycline, which relieved symptoms. Forty-six of the 83 were given TFLX as initial treatment, and the remaining 37 not responding to clarithromycin (CAM) and azithromycin (AZM) were also treated with TFLX. This drug was effective in 41 (89.1%) of the 46 patients initially treated with TFLX and TFLX was effective in all 37 (100%) patients not responding to CAM and AZM. Side effects of TFLX included mild diarrhea, observed in 3 patients, but no patients had joint symptoms or convulsions.
authors.affiliation: Department of Pediatrics, Asahikawa Kosei Hospital.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sakata
mesh_terms: D000293:Adolescent; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D024841:Fluoroquinolones / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D009287:Naphthyridines / Q000009:adverse effects / Q000627:therapeutic use*; D011019:Pneumonia, Mycoplasma / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; C055185:tosufloxacin